A Pill for Sexual Desire in Female Cancer Survivors: Too Good to Be True?
Mené sur 230 patientes ayant survécu à un cancer du sein ou à un cancer gynécologique, cet essai de phase II évalue l'efficacité du bupropion (un agent dopaminergique) pour améliorer le désir sexuel
Cancer survivors often experience sexual dysfunction across multiple cancer types and stages of disease. Disruption of sexual function is often persistent during and after cancer therapies, affecting quality of life. Multiple studies have highlighted the diversity of ways that cancer treatment modalities can lead to sexual dysfunction. Despite a range of literature highlighting this pervasive treatment toxicity, interventions that effectively address this subject are limited and rarely used.
Journal of Clinical Oncology , éditorial en libre accès, 2020